Accessibility Statement Skip Navigation
  • Resources
  • Blog
  • Journalists
  • Webcasts
  • Data Privacy
  • Français
  • my CNW 
    • Login
    • Register
  • Client Login 
    • Online Member Centre
    • Next Gen Communications Cloud
    • Cision Communications Cloud®
  • Sign Up
  • Send a Release
Return to PR Newswire homepage
  • News
  • Products
  • Contact
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
Advanced Search
  • News in Focus
      • Browse News Releases

      • All News Releases
      • All Public Company
      • News Releases Overview

      • Multimedia Gallery

      • All Multimedia
      • All Photos
      • All Videos
      • Multimedia Gallery Overview

      • Trending Topics

      • All Trending Topics
  • Business
      • Auto & Transportation

      • All Automotive & Transportation
      • Aerospace, Defense
      • Air Freight
      • Airlines & Aviation
      • Automotive
      • Maritime & Shipbuilding
      • Railroads and Intermodal Transportation
      • Supply Chain/Logistics
      • Transportation, Trucking & Railroad
      • Travel
      • Trucking and Road Transportation
      • Auto & Transportation Overview

      • View All Auto & Transportation

      • Business Technology

      • All Business Technology
      • Blockchain
      • Broadcast Tech
      • Computer & Electronics
      • Computer Hardware
      • Computer Software
      • Data Analytics
      • Electronic Commerce
      • Electronic Components
      • Electronic Design Automation
      • Financial Technology
      • High Tech Security
      • Internet Technology
      • Nanotechnology
      • Networks
      • Peripherals
      • Semiconductors
      • Business Technology Overview

      • View All Business Technology

      • Entertain­ment & Media

      • All Entertain­ment & Media
      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • Entertain­ment & Media Overview

      • View All Entertain­ment & Media

      • Financial Services & Investing

      • All Financial Services & Investing
      • Accounting News & Issues
      • Acquisitions, Mergers and Takeovers
      • Banking & Financial Services
      • Bankruptcy
      • Bond & Stock Ratings
      • Conference Call Announcements
      • Contracts
      • Cryptocurrency
      • Dividends
      • Earnings
      • Earnings Forecasts & Projections
      • Financing Agreements
      • Insurance
      • Investments Opinions
      • Joint Ventures
      • Mutual Funds
      • Private Placement
      • Real Estate
      • Restructuring & Recapitalization
      • Sales Reports
      • Shareholder Activism
      • Shareholder Meetings
      • Stock Offering
      • Stock Split
      • Venture Capital
      • Financial Services & Investing Overview

      • View All Financial Services & Investing

      • General Business

      • All General Business
      • Awards
      • Commercial Real Estate
      • Corporate Expansion
      • Earnings
      • Environmental, Social and Governance (ESG)
      • Human Resource & Workforce Management
      • Licensing
      • New Products & Services
      • Obituaries
      • Outsourcing Businesses
      • Personnel Announcements
      • Real Estate Transactions
      • Residential Real Estate
      • Small Business Services
      • Socially Responsible Investing
      • Surveys, Polls and Research
      • Trade Show News
      • General Business Overview

      • View All General Business

  • Science & Tech
      • Consumer Technology

      • All Consumer Technology
      • Artificial Intelligence
      • Blockchain
      • Cloud Computing/Internet of Things
      • Computer Electronics
      • Computer Hardware
      • Computer Software
      • Consumer Electronics
      • Cryptocurrency
      • Data Analytics
      • Electronic Commerce
      • Electronic Gaming
      • Financial Technology
      • Mobile Entertainment
      • Multimedia & Internet
      • Peripherals
      • Social Media
      • STEM (Science, Tech, Engineering, Math)
      • Supply Chain/Logistics
      • Wireless Communications
      • Consumer Technology Overview

      • View All Consumer Technology

      • Energy & Natural Resources

      • All Energy
      • Alternative Energies
      • Chemical
      • Electrical Utilities
      • Gas
      • General Manufacturing
      • Mining
      • Mining & Metals
      • Oil & Energy
      • Oil and Gas Discoveries
      • Utilities
      • Water Utilities
      • Energy & Natural Resources Overview

      • View All Energy & Natural Resources

      • Environ­ment

      • All Environ­ment
      • Conservation & Recycling
      • Environmental Issues
      • Environmental Policy
      • Environmental Products & Services
      • Green Technology
      • Natural Disasters
      • Environ­ment Overview

      • View All Environ­ment

      • Heavy Industry & Manufacturing

      • All Heavy Industry & Manufacturing
      • Aerospace & Defense
      • Agriculture
      • Chemical
      • Construction & Building
      • General Manufacturing
      • HVAC (Heating, Ventilation and Air-Conditioning)
      • Machinery
      • Machine Tools, Metalworking and Metallurgy
      • Mining
      • Mining & Metals
      • Paper, Forest Products & Containers
      • Precious Metals
      • Textiles
      • Tobacco
      • Heavy Industry & Manufacturing Overview

      • View All Heavy Industry & Manufacturing

      • Telecomm­unications

      • All Telecomm­unications
      • Carriers and Services
      • Mobile Entertainment
      • Networks
      • Peripherals
      • Telecommunications Equipment
      • Telecommunications Industry
      • VoIP (Voice over Internet Protocol)
      • Wireless Communications
      • Telecomm­unications Overview

      • View All Telecomm­unications

  • Lifestyle & Health
      • Consumer Products & Retail

      • All Consumer Products & Retail
      • Animals & Pets
      • Beers, Wines and Spirits
      • Beverages
      • Bridal Services
      • Cannabis
      • Cosmetics and Personal Care
      • Fashion
      • Food & Beverages
      • Furniture and Furnishings
      • Home Improvement
      • Household, Consumer & Cosmetics
      • Household Products
      • Jewelry
      • Non-Alcoholic Beverages
      • Office Products
      • Organic Food
      • Product Recalls
      • Restaurants
      • Retail
      • Supermarkets
      • Toys
      • Consumer Products & Retail Overview

      • View All Consumer Products & Retail

      • Entertain­ment & Media

      • All Entertain­ment & Media
      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • Entertain­ment & Media Overview

      • View All Entertain­ment & Media

      • Health

      • All Health
      • Biometrics
      • Biotechnology
      • Clinical Trials & Medical Discoveries
      • Dentistry
      • FDA Approval
      • Fitness/Wellness
      • Health Care & Hospitals
      • Health Insurance
      • Infection Control
      • International Medical Approval
      • Medical Equipment
      • Medical Pharmaceuticals
      • Mental Health
      • Pharmaceuticals
      • Supplementary Medicine
      • Health Overview

      • View All Health

      • Sports

      • All Sports
      • General Sports
      • Outdoors, Camping & Hiking
      • Sporting Events
      • Sports Equipment & Accessories
      • Sports Overview

      • View All Sports

      • Travel

      • All Travel
      • Amusement Parks and Tourist Attractions
      • Gambling & Casinos
      • Hotels and Resorts
      • Leisure & Tourism
      • Outdoors, Camping & Hiking
      • Passenger Aviation
      • Travel Industry
      • Travel Overview

      • View All Travel

  • Policy & Public Interest
      • Policy & Public Interest

      • All Policy & Public Interest
      • Advocacy Group Opinion
      • Animal Welfare
      • Canadian Federal Government
      • Canadian Municipal Government
      • Canadian Provincial Government
      • Corporate Social Responsibility
      • Domestic Policy
      • Economic News, Trends, Analysis
      • Education
      • Environmental
      • European Government
      • FDA Approval
      • Federal and State Legislation
      • Federal Executive Branch & Agency
      • Foreign Policy & International Affairs
      • Homeland Security
      • Labor & Union
      • Legal Issues
      • Natural Disasters
      • Not For Profit
      • Patent Law
      • Public Safety
      • Trade Policy
      • Policy & Public Interest Overview

      • View All Policy & Public Interest

  • People & Culture
      • People & Culture

      • All People & Culture
      • Aboriginal, First Nations & Native American
      • African American
      • Asian American
      • Children
      • Diversity, Equity & Inclusion
      • Hispanic
      • Lesbian, Gay & Bisexual
      • Men's Interest
      • People with Disabilities
      • Religion
      • Senior Citizens
      • Veterans
      • Women
      • People & Culture Overview

      • View All People & Culture

  • Advanced Search
  • Overview
  • Cision Communications Cloud®
  • Monitoring
  • Distribution
  • Multimedia
  • Guaranteed Paid Placement
  • AI Tools
  • IR
  • Become a Client
  • Request a Demo
  • Editorial Bureaus
  • Partnerships
  • General Enquiries
  • Media
  • Worldwide Offices
  • Hamburger menu
  • Cision Canada
  • Send a Release
  • FR
    • Phone

    • 877-269-7890 from 8 AM - 10 PM ET

    • ALL CONTACT INFO
    • Contact Cision

      877-269-7890
      from 8 AM - 10 PM ET

  • Send a Release
  • Sign Up
  • Resources
  • Blog
  • Journalists
  • Webcasts
  • GDPR
  • News in Focus
    • Browse All News
    • Multimedia Gallery
    • Trending Topics
  • Business
    • Auto & Transportation
    • Business Technology
    • Entertain­ment & Media
    • Financial Services & Investing
    • General Business
  • Science & Tech
    • Consumer Technology
    • Energy & Natural Resources
    • Environ­ment
    • Heavy Industry & Manufacturing
    • Telecomm­unications
  • Lifestyle & Health
    • Consumer Products & Retail
    • Entertain­ment & Media
    • Health
    • Sports
    • Travel
  • Policy & Public Interest
    • Policy & Public Interest
  • People & Culture
    • People & Culture
  • Send a Release
  • Sign Up
  • Resources
  • Blog
  • Journalists
  • Webcasts
  • GDPR
  • Overview
  • Cision Communications Cloud®
  • Monitoring
  • Distribution
  • Multimedia
  • Guaranteed Paid Placement
  • AI Tools
  • IR
  • Send a Release
  • Sign Up
  • Resources
  • Blog
  • Journalists
  • Webcasts
  • GDPR
  • Become a Client
  • Request a Demo
  • Editorial Bureaus
  • Partnerships
  • General Enquiries
  • Media
  • Worldwide Offices
  • Send a Release
  • Sign Up
  • Resources
  • Blog
  • Journalists
  • Webcasts
  • GDPR

PHARMASCIENCE ANNOUNCES $120 MILLION EXPANSION OF CANDIAC INJECTABLE MANUFACTURING FACILITIES Français


News provided by

Pharmascience Inc.

Oct 27, 2023, 10:30 ET

Share this article

Share toX

Share this article

Share toX

This major project will enhance Canada's domestic medicine supply, boost exports

CANDIAC, QC, Oct. 27, 2023 /CNW/ - Pharmascience Inc. (Pharmascience) is pleased to announce a major expansion of its sterile injectable manufacturing facility in Candiac, Québec, supported by partners with Innovation, Science and Economic Development Canada's Strategic Innovation Fund and by the Government of Québec through Investissement Québec.

Continue Reading
PHARMASCIENCE ANNOUNCES $120 MILLION EXPANSION OF CANDIAC INJECTABLE MANUFACTURING FACILITIES (CNW Group/Pharmascience Inc.)
PHARMASCIENCE ANNOUNCES $120 MILLION EXPANSION OF CANDIAC INJECTABLE MANUFACTURING FACILITIES (CNW Group/Pharmascience Inc.)

As the largest Canadian-owned pharmaceutical company, Pharmascience is dedicated to building on its 40 years of expertise in pharmaceutical manufacturing by investing in growth in Québec. This major expansion project will allow Pharmascience to triple its injectable manufacturing capacity and has numerous benefits to the health of Canadians and to patients worldwide.

With the new plant expansion coming online in 2026, this project will:

  • Build on our strengths in R&D to attract more Contract Development and Manufacturing (CMO and CDMO) projects
  • Improve Canada's domestic biomanufacturing capabilities and ability to meet our pharmaceutical supply chain needs
  • Increase manufacturing efficiency and result in faster response times to product shortages or urgent health challenges
  • Fully implant Pharmascience as the Canadian leader in specialized, cytotoxic and high-potency injectable pharmaceutical manufacturing
Quotes

"This major expansion project is the continuation of Pharmascience's vision to be the Canadian leader in biomanufacturing of both generic and innovative products. We are proud to invest in the continued growth of Pharmascience, building on our 40 years of experience in the sector, to bring affordable, high-quality medicines to patients in Canada and around the world."

-  David W. Goodman, PhD, Executive Chairman, Pharmascience

"Today's announcement shows that Pharmascience is determined to support local manufacturing  and that we believe in the need to invest in Québec and in Canada. We are proud to announce this major project that will firmly cement our role as leaders in Canadian pharmaceutical manufacturing. This project proves that, with the support of governments, we can support local manufacturing and our domestic capacity to secure pharmaceutical supply chain security as well as the strength of our healthcare system."

-  Martin Arès, CEO, Pharmascience

"Pharmascience's work to update and expand its Quebec facility is a move that supports the strategic growth of Canada's life sciences sector and increases our cutting-edge biomanufacturing capabilities. This project not only ensures Canadians have access to critical medicines but also helps to strengthen and expand Canada's growing biomanufacturing and life sciences industry."

-  The Honourable François-Philippe Champagne, Minister of Innovation, Science and Industry

"Quebec is fast becoming a major hub for the biomanufacturing and life sciences sector, both in Canada and around the world. By expanding the capacity of an already impressive facility, this investment by the governments of Canada and Quebec will further strengthen that, while creating high-level and well-paying jobs in the Montréal area."

-  The Honourable Soraya Martinez Ferrada, Minister of Tourism and Minister responsible for the Economic Development Agency of Canada for the Regions of Quebec

"Our government is continuing to build a strong and innovative Québec life sciences industry. Focusing on major projects such as Pharmascience's will strengthen the foundation of this strategic sector and bolster our local supply."

-  Pierre Fitzgibbon, Minister of Economy, Innovation and Energy, Minister Responsible for Regional Economic Development and Minister Responsible for the Metropolis and the Montréal Region

"Our priority is to promote self-sufficiency in terms of supply and support innovation in the health field to improve our network's performance, as mentioned in the Plan santé. By supporting the Pharmascience project, we are leveraging local expertise to better meet the needs of Quebecers."

-  Christian Dubé, Minister of Health

"The expansion of Pharmascience's facilities in Candiac is an eloquent testimony to the commitment of this major Quebec family business to maintaining the pharmaceutical supply chain for the benefit of all Canadians. Counting Pharmascience among its corporate citizens is a source of pride for the municipal council. Its reputation and worldwide success can only benefit the entire community."

-  Normand Dyotte, Mayor of Candiac

Quick Facts
  • This project will triple Pharmascience's current injectable manufacturing capacity from its 2021 level, with the addition of new, more efficient equipment.
  • The new facility comprises approximately 26,000 square feet of new manufacturing space and equipment, and a retrofit of approximately 7,500 square feet to Pharmascience's existing manufacturing facilities.
  • Valued at a total of $120 million, this project is supported by the Government of Canada's Strategic Innovation Fund at $29.77 million and by the Government of Québec through Investissement Québec at $24.75 million.
  • 50 new high-skilled advanced manufacturing jobs will be created as a result of the project, with the project supporting an additional 300 jobs.
  • Pharmascience will be able to invest approximately $40-50 million every year in R&D in Canada.
  • With only 12% of Canada's drug supply produced domestically, this project will add much needed domestic manufacturing capacity to protect Canada's pharmaceutical supply chain.
ABOUT PHARMASCIENCE INC.

Founded in 1983, Pharmascience Inc. is the largest pharmaceutical employer in Quebec. With 1,500 employees proudly headquartered in Montreal, Pharmascience Inc. is a full-service, privately-owned pharmaceutical company with strong roots in Canada and a growing global reach, with product distribution in over 50 countries. Ranked 50th among Canada's top 100 Research and Development (R&D) investors in 2022, with $40-50 million in annual investment, Pharmascience Inc. is among the largest drug manufacturers in Canada.

Pharmascience Inc. has strong values based on the importance of investing in its employees and young people. Through various programs and initiatives, the company ensures it supports their personal development and life. In 2023, Pharmascience Inc. has proudly been recognized for its investments by being selected as one of Canada's Top Employers for Young People as part of Canada's Top 100 Employers. Also as of 2023, Pharmascience is now certified as a Great Place to Work for its second year in a row.

SOURCE Pharmascience Inc.

For more information, please contact: Justin Meloche, 514-995-9704, [email protected]

Modal title

Organization Profile

Pharmascience Inc.

    Also from this source

  • Pharmascience Canada strengthens its commitment to patients with an antihistamine treatment

  • Pharmascience Canada launches Pr pms-PALBOCICLIB, a treatment for breast cancer

  • Pharmascience Canada launches a new medication for its patient

Contact Cision

  • 866-245-2317
    from 8 AM - 10 PM ET
  • Become a Client
  • Request a Demo
  • Editorial Bureaus
  • Partnerships
  • General Enquiries
  • Media

Products

  • Cision Communications Cloud®
  • Media Monitoring
  • Content Distribution
  • Multimedia Distribution
  • Measurement & Analytics
  • Investor Relations

About

  • About Cision Canada
  • About Cision
  • Media Partners
  • Careers
  • Accessibility Statement
  • APAC
  • APAC - Simplified Chinese
  • APAC - Traditional Chinese
  • Brazil
  • Canada
  • Czech
  • Denmark
  • Finland
  • France
  • Germany
  • India
  • Indonesia
  • Israel
  • Japan
  • Korea
  • Mexico
  • Middle East
  • Middle East - Arabic
  • Netherlands
  • Norway
  • Poland
  • Portugal
  • Russia
  • Slovakia
  • Spain
  • Sweden
  • United States
  • Vietnam

My Services

  • All News Releases
  • Online Member Centre
  • Next Gen Communications Cloud
  • Cision Communications Cloud®
  • my CNW

Do not sell or share my personal information:

  • Submit via [email protected] 
  • Call Privacy toll-free: 877-297-8921

Contact Cision

Products

About

My Services
  • All News Releases
  • Online Member Centre
  • Next Gen Communications Cloud
  • Cision Communications Cloud
  • my CNW
877-269-7890
from 8 AM - 10 PM ET
  • Terms of Use
  • Information Security Policy
  • Site Map
  • Cookie Settings
  • Accessibility Statement
Copyright © 2025 CNW Group Ltd. All Rights Reserved. A Cision company.